Anticonvulsive pharmaceutical compositions

A method of limiting or reducing the incidence of visual side-effects caused by an active ingredient that increases GABA levels or activates GABA receptors in a mammal, the method comprising administering to a subject in need thereof an effective amount of taurine;

• wherein said active ingredient that increases GABA levels or activates GABA receptors is at least one selected from the group consisting of:
• a GABA-aminotransferase inhibitor selected from the group consisting of:
• 4-amino-5-hexenoic acid, its racemic mixture or an active isomer, valproate, (1R,3S,4S)-3-amino-4-fluorocyclopentane-1-carboxylic acid, (1R,4S)-4-amino-2-cyclopentene-1-carboxylic acid, (1S,4R)-4-amino-2-cyclopentene-1-carboxylic acid, (4R)-4-amino-1-cyclopentene-1-carboxylic acid, (4S)-4-amino-1-cyclopentene-1-carboxylic acid, (S)-4-amino-4,5-dihydro-2-thiophenecarboxylic acid, 1H-tetrazole-5-(alpha-vinyl-propanamine), 2,4-diaminobutanoate, 2-oxoadipic acid, 2-oxoglutarate, 2-thiouracil, 3-chloro-4-aminobutanoate, 3-methyl-2-benzothiazolone hydrazone hydrochloride, 3-phenyl-4-aminobutanoate, 4-ethynyl-4-aminobutanoate, 5-diazouracil, 5-fluorouracil, aminooxyacetate, beta-alanine, cycloserine, and D-cycloserine,
• the GABA transporter blocker tiagabine, and
• a GABA receptor agonist or modulator selected from the group consisting of:
• topiramate, felbamate, tramadol, oxcarbazepine, carbamazepine, eszopiclone, zopiclone, baclofen, imidazopyridines, zaleplon, zolpidem, zopiclone phenytoin, propofol, phenytoin, benzodiazepines, and barbiturates;
• wherein the visual side-effect is at least one of damage to the retina, constriction of the visual field, dysfunction of central vision, reduced visual acuity, loss of color discrimination, and loss of contrast sensitivity.